Delivery Order SPE2DB24D2205-SPE2DB25FEHGG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $10,030.26, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, represents a competitive award with no set-aside designation and a completion date of August 6, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a delivery order valued at $3,214.62 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. The contract, issued on July 30, 2025, is a firm fixed price delivery order with an ultimate completion date of July 31, 2025. The award carries no set-aside designation and represents a competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,915.60 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion scheduled for August 20, 2025. This delivery order represents a firm fixed-price procurement with no set-aside designation, competitively awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,437.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (adalimumab) pen auto-injectors containing 40 mg/0.4 mL doses. This non-set-aside contract represents a single delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of HUMIRA (adalimumab) pen injections at 40 mg/0.4 mL. This firm fixed-price delivery order, valued at $27,237.04, represents a non-competitive award issued under an existing indefinite delivery contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 15, 2025. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,411.86 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable pharmaceutical product used for treating inflammatory conditions. This firm fixed-price delivery order, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,643.55 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply fulfillment supporting...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHGGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $73,860.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) PEN 40 mg/0.4 mL auto-injectors under a firm fixed-price contract type. The award was made on September 9, 2025, with an ultimate completion date of September 10, 2025, with performance to occur at the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued without a set-aside designation, indicating the award was competitively procured in an open competition environment. This delivery order is issued against AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999.00 through December 2026. As the prime contractor, AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare systems and other government agencies including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its capability to meet specialized pharmaceutical supply requirements across multiple therapeutic domains through competitively awarded arrangements with the DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $73.9k | 9/9/25 |